AR085538A1 - Vacunas para la tuberculosis (tb) basadas en el direccionamiento hacia las celulas dendriticas (dc) - Google Patents

Vacunas para la tuberculosis (tb) basadas en el direccionamiento hacia las celulas dendriticas (dc)

Info

Publication number
AR085538A1
AR085538A1 ARP120100964A ARP120100964A AR085538A1 AR 085538 A1 AR085538 A1 AR 085538A1 AR P120100964 A ARP120100964 A AR P120100964A AR P120100964 A ARP120100964 A AR P120100964A AR 085538 A1 AR085538 A1 AR 085538A1
Authority
AR
Argentina
Prior art keywords
vaccines
tuberculosis
antigens
addressing
dendritic cells
Prior art date
Application number
ARP120100964A
Other languages
English (en)
Inventor
Gerard Zurawski
Jacques F Banchereau
Yves Levy
Patrick Lecine
Original Assignee
Baylor Res Inst
Inst Nat Sante Rech Med
Agence Nationale De Rech S Sur Le Sida Et Les Hepatitis Virales
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Inst, Inst Nat Sante Rech Med, Agence Nationale De Rech S Sur Le Sida Et Les Hepatitis Virales filed Critical Baylor Res Inst
Publication of AR085538A1 publication Critical patent/AR085538A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4615Dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/462Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622Antigen presenting cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4648Bacterial antigens
    • A61K39/464817Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6056Antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Composiciones y métodos que comprenden conjugados de anticuerpos monoclonales de alta afinidad contra diversos receptores de las DC. Se trata de proteínas de fusión con antígenos dirigidos a las DC que se preparan mediante la conjugación de diversas proteínas antigénicas de M. tuberculosis con anticuerpos monoclonales de alta afinidad contra receptores de las DC, con las que pueden desarrollarse vacunas para los seres humanos sobre la base del direccionamiento hacia las DC. Los resultados de los estudios que se describen en la presente reflejan que las vacunas que comprenden antígenos de la tuberculosis pueden evocar una respuesta potente de memoria con especificidad por los antígenos en las células T, que da como resultado la secreción de IFNg.
ARP120100964A 2011-03-22 2012-03-22 Vacunas para la tuberculosis (tb) basadas en el direccionamiento hacia las celulas dendriticas (dc) AR085538A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161466292P 2011-03-22 2011-03-22

Publications (1)

Publication Number Publication Date
AR085538A1 true AR085538A1 (es) 2013-10-09

Family

ID=46877533

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100964A AR085538A1 (es) 2011-03-22 2012-03-22 Vacunas para la tuberculosis (tb) basadas en el direccionamiento hacia las celulas dendriticas (dc)

Country Status (6)

Country Link
US (1) US20120244155A1 (es)
EP (1) EP2688591A4 (es)
AR (1) AR085538A1 (es)
CA (1) CA2830987A1 (es)
TW (1) TW201305193A (es)
WO (1) WO2012129227A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體(dc-asgpr)接合抗原呈現細胞之藥劑
CA2685954A1 (en) * 2007-05-03 2008-11-13 Agency For Science, Technology And Research Antibodies binding to an intracellular prl-1 or prl-3 polypeptide
CA2754743C (en) 2009-03-10 2020-08-25 Baylor Research Institute Antigen presenting cell targeted anti-viral vaccines
AU2010222942B2 (en) 2009-03-10 2013-01-10 Baylor Research Institute Anti-CD40 antibodies and uses thereof
CA2916694C (en) 2013-06-28 2023-01-17 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
MX2016009072A (es) * 2014-01-09 2017-05-08 Transgene Sa Fusion de antigenos micobacterianos heterooligomericos.
EP3094652B1 (en) 2014-01-13 2021-09-29 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
IL300029A (en) 2014-05-16 2023-03-01 Baylor Res Institute Methods and preparations for the treatment of autoimmune and inflammatory conditions
EP3164417A1 (en) 2014-07-01 2017-05-10 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
ES2893584T3 (es) * 2015-06-10 2022-02-09 Univ Tokyo Adyuvante para vacunas, vacuna y procedimiento de inducción de inmunidad
UY37141A (es) 2016-03-04 2017-09-29 Jn Biosciences Llc Anticuerpos dirigidos a tigit
KR101892598B1 (ko) * 2017-01-18 2018-08-28 연세대학교 산학협력단 수지상 세포를 포함하는 결핵 백신 부스터용 조성물
KR101828044B1 (ko) * 2017-01-18 2018-02-09 연세대학교 산학협력단 수지상 세포 및 항생제를 포함하는 결핵 예방 또는 치료용 조성물
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
CN109679908B (zh) * 2019-02-25 2020-04-21 上海尚泰生物技术有限公司 一种制备高纯度人树突状细胞的方法及其应用
US20220169737A1 (en) * 2019-04-05 2022-06-02 Dren Bio, Inc. Methods of depleting disease causing agents via antibody targeted phagocytosis
PE20231078A1 (es) 2020-06-02 2023-07-17 Arcus Biosciences Inc Anticuerpos anti-tigit
US12037399B2 (en) 2020-10-07 2024-07-16 Dren Bio, Inc. Anti-Dectin-1 antibodies and methods of use thereof
CN112119977B (zh) * 2020-10-15 2021-10-19 中国人民解放军军事科学院军事医学研究院 Cd317诱导的抑郁和记忆损伤的小鼠模型的构建方法及其应用
WO2024160956A1 (en) 2023-02-02 2024-08-08 Institut National de la Santé et de la Recherche Médicale Anti-tuberculosis vaccine targeting selected mycobacterium tuberculosis protective antigens to dendritic cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037510B2 (en) * 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
US20020025315A1 (en) * 1998-01-14 2002-02-28 Naveen N. Anand Chimeric antibodies for delivery of antigens to selected cells of the immune system
US20040146948A1 (en) * 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
WO2007103048A2 (en) * 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
TWI422594B (zh) * 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體(dc-asgpr)接合抗原呈現細胞之藥劑
CA2754743C (en) * 2009-03-10 2020-08-25 Baylor Research Institute Antigen presenting cell targeted anti-viral vaccines
AU2010291939B2 (en) * 2009-09-14 2012-11-15 Baylor Research Institute Vaccines directed to Langerhans cells
US20110274653A1 (en) * 2010-05-07 2011-11-10 Baylor Research Institute Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+ t cells

Also Published As

Publication number Publication date
EP2688591A1 (en) 2014-01-29
EP2688591A4 (en) 2014-10-01
CA2830987A1 (en) 2012-09-27
TW201305193A (zh) 2013-02-01
WO2012129227A1 (en) 2012-09-27
US20120244155A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
AR085538A1 (es) Vacunas para la tuberculosis (tb) basadas en el direccionamiento hacia las celulas dendriticas (dc)
CY1120976T1 (el) Δις ειδικα αντισωματα igg σαν παραγοντες ενεργοποιησης τ κυτταρων
AR076106A1 (es) Anticuerpos anti-cd40 y usos de los mismos
AR101455A1 (es) Molécula portadora
AR076107A1 (es) Vacunas anti-virales dirigidas contra celulas presentadoras de antigenos
CL2019002036A1 (es) Anticuerpo contra bcma y su uso.
BR112015010436A2 (pt) Anticorpos anti-notch3 e conjugados anticorpo-fármaco
CL2011003091A1 (es) Composicion que comprende conjugado covalente entre hemoglobina funcional y nativa y al menos una molecula de polietilenglicol; metodo para preparar composicion; uso de dicha composicion para producir medicina de transfusion.
CO6771458A2 (es) Conjugados de anticuerpo-fármaco
CL2015001900A1 (es) Vacunas con mayor densidad de antigeno carbohidrato y nuevo adyuvante de saponina.
CO7160026A2 (es) Vacuna contra mycoplasma hyopneumoniae
CY1115091T1 (el) Διειδικες πρωτεϊνες προσδεσης αντιγονων
AR091961A1 (es) Inmunoconjugados y anticuerpos anti-etbr (receptor de endotelina b)
PA8718601A1 (es) Anticuerpos anti-5t4 y sus usos
MX2014005372A (es) Molecula portadora que comprende un antigeno spr0096 y un spr2021.
AR075851A1 (es) Vacunas anti-cancer dirigidas contra celulas presentadoras de antigenos
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
CL2012003299A1 (es) Vacuna que comprende uno o mas antigenos, uno o mas oligonucleotidos inmunoestimuladores aislados y colesterol; metodo para inducir una respuesta inmune antigeno específica en un sujeto que necesita de la misma.
AR092896A1 (es) Composiciones inmunogenicas
CO6561819A2 (es) Vectores para vacunas y método para potenciar respuestas inmunes
BR112015016817A8 (pt) métodos para derivar um sacarídeo, para conjugar um derivado de sacarídeo e para incitar uma resposta imune em um mamífero, derivado de sacarídeo, conjugado de um derivado de sacarídeo, composição farmacêutica, e, uso de um conjugado ou composição farmacêutica
AR096123A1 (es) Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coagulación
AR088220A1 (es) Activacion de celulas dendriticas humanas por el receptor de dectina-1 o de tipo toll 2 (tlr2) en el control de la alergia y el asma
ES2656474T3 (es) Osteopontina láctea de origen mamífero para potenciar la capacidad de respuesta inmune

Legal Events

Date Code Title Description
FB Suspension of granting procedure